文献速递药物相互作用特殊人群用药治疗药物监测与药物基因组学

双特异性T细胞衔接器的临床药理学特征:基于FDA批准的总结

Clinical Pharmacology Characterization of Bispecific T-Cell Engagers: A Summary Based on FDA Approvals.
PubMed 文献 · Clin Pharmacol Ther · 2025-08-05

本文综述了截至2025年5月FDA批准的9种双特异性T细胞衔接器(Bi-TCE)的临床药理学特征,涵盖剂量策略、一般临床药理学评价及细胞因子相关药物相互作用评估,旨在理解当前实践并识别知识缺口。

要点

  • Bi-TCE剂量策略包括阶梯剂量和全治疗剂量选择标准及延迟后重启分析。
  • 特定人群药代动力学(如器官损伤、儿科)和免疫原性信息是评价重点。
  • 细胞因子相关DDI评估涉及细胞因子谱、风险缓解策略及PBPK模型局限性。

核心结论

  • 综述总结了9种FDA批准Bi-TCE的临床药理学特征,并指出未来需优化剂量选择、应用PBPK模型及拓展实体瘤和非肿瘤适应症。

研究设计与样本

  • 综述性研究,基于截至2025年5月FDA批准的9种Bi-TCE(7种用于血液肿瘤,2种用于实体瘤)。

主要发现

  • 剂量策略部分讨论了阶梯剂量和全治疗剂量选择标准、后续周期剂量方案进一步优化的可能性及剂量延迟后重启策略的支持分析。
  • 一般临床药理学评价部分总结了药代动力学特性及其对剂量策略的影响、特定人群(如器官损伤、儿科)的药代动力学、药效学特性和免疫原性信息。
  • 细胞因子相关DDI部分讨论了细胞因子谱、风险缓解策略以及基于生理的药代动力学(PBPK)模型及其局限性。

临床怎么用

  • 临床药学智能体医生可参考本综述中Bi-TCE的剂量策略、特殊人群药代动力学及细胞因子相关DDI评估要点,用于临床用药决策。

局限性

  • 本综述基于FDA已批准Bi-TCE的公开信息,可能未涵盖未批准产品或最新研究数据,且PBPK模型存在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bispecific T-cell engagers (Bi-TCEs) have demonstrated clinical efficacy and safety, with 7 approved for hematological cancers and 2 approved for solid tumors by the US Food and Drug Administration (FDA) as of May 2025. Its intricate mechanism of action through the formation of a trimer involving Bi-TCE, T cell, and tumor cell presents challenges to clinical development requiring special strategies for multiple disciplines. This review summarizes key clinical pharmacology characterizations of these 9 FDA-approved Bi-TCEs to understand the current practice and to identify potential knowledge gaps. The topics covered include dosing strategies, general clinical pharmacology evaluations, and cytokine-related drug-drug interaction (DDI) assessment. The dosing strategy part discusses the criteria for step-up dose and full treatment dose selection, the potential for further optimization of dose regimen in later cycles, and the analyses supporting the restarting strategy after dosage delay. The section on general clinical pharmacology evaluations summarizes pharmacokinetic (PK) property and its impact on dosing strategy, PK in specific populations (e.g., organ impairment, pediatrics), pharmacodynamics property, and immunogenicity information. The cytokine-related DDI part discusses cytokine profiles, risk mitigation strategy, and physiologically based PK (PBPK) models and their limitations. Finally, future perspectives are provided regarding efficient dose selection, PBPK modeling application, and Bi-TCEs for solid tumors and non-oncology indications.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang T, Wang YM, Sun Q, et al. Clinical Pharmacology Characterization of Bispecific T-Cell Engagers: A Summary Based on FDA Approvals. Clin Pharmacol Ther. 2025. PMID: 40762425. doi:10.1002/cpt.70020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。